Quality-of-Life Changes Following Cisplatin-Based Chemotherapy in Patients with Lung Cancer and Cisplatin-Induced Peripheral Neuropathy: A Sex-Stratified Analysis
4 affiliations
- 1Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
- 2Center for Physical Medicine and Rehabilitation, University Clinical Centre of Serbia, 11000 Belgrade, Serbia
- 3Clinic for Rehabilitation “Dr. Miroslav Zotovic”, 11000 Belgrade, Serbia
- 4Meliora Medica, 11000 Belgrade, Serbia
Abstract
Background/Objectives: Peripheral neuropathy is an important neurotoxic complication of cisplatin-based chemotherapy, but its occurrence may be accompanied by different changes across specific aspects of quality of life (QoL). This study aimed to evaluate longitudinal QoL changes in patients with lung cancer and determine whether they differed between women and men. Methods: This longitudinal analysis included 40 patients with lung cancer who developed cisplatin-induced peripheral neuropathy during cisplatin-based chemotherapy. QoL was assessed before chemotherapy and after four cycles using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy–Lung (FACT-L). Changes over time, sex differences, and time × sex interactions were evaluated using a repeated-measures General Linear Model. p-values were adjusted for multiple comparisons using the Benjamini–Hochberg procedure. Results: Of 40 patients, 27 (67.5%) were men and 13 (32.5%) were women. On the EORTC QLQ-C30, no significant time effects were observed after adjustment for multiple comparisons. On the FACT-L, Social/Family Well-Being decreased significantly (FDR-adjusted p = 0.024), whereas Lung Cancer Subscale scores increased significantly (FDR-adjusted p = 0.044). No significant main effects of sex were identified after adjustment for multiple comparisons. No significant time × sex interactions were identified for any outcome. Conclusions: Significant changes were observed in selected QoL outcomes during cisplatin-based chemotherapy, while no significant sex-related differences in longitudinal changes were identified. Given the small and sex-imbalanced sample, the absence of significant interactions should not be interpreted as evidence of equivalent QoL changes between women and men.
Related
- Baseline Peripheral Neuropathy Predicts Clinically Significant Neuropathy During Paclitaxel Treatment Following Oxaliplatin-based Chemotherapy.
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
- Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study
- Case Report: Bilateral optic disc edema with papillophlebitis-like features following combined cisplatin and capecitabine chemotherapy
- Selected Ion Channels in Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Translational Limits
BibTeX
@article{vujadinovic2026qualityoflife,
title = {{Quality-of-Life Changes Following Cisplatin-Based Chemotherapy in Patients with Lung Cancer and Cisplatin-Induced Peripheral Neuropathy: A Sex-Stratified Analysis}},
author = {Sanja Tomanovic Vujadinovic and Nevena Krstic and Ivan Selakovic and Milica Aleksic and Aleksandra Vidakovic and Emilija Dubljanin and Dragana Jovanovic and Nela Ilic},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213515},
url = {https://www.mdpi.com/2072-6694/18/21/3515},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Quality-of-Life Changes Following Cisplatin-Based Chemotherapy in Patients with Lung Cancer and Cisplatin-Induced Peripheral Neuropathy: A Sex-Stratified Analysis
AU - Sanja Tomanovic Vujadinovic
AU - Nevena Krstic
AU - Ivan Selakovic
AU - Milica Aleksic
AU - Aleksandra Vidakovic
AU - Emilija Dubljanin
AU - Dragana Jovanovic
AU - Nela Ilic
PY - 2026
DA - 2026/11/01
JO - Cancers
DO - 10.3390/cancers18213515
UR - https://www.mdpi.com/2072-6694/18/21/3515
AB - Background/Objectives: Peripheral neuropathy is an important neurotoxic complication of cisplatin-based chemotherapy, but its occurrence may be accompanied by different changes across specific aspects of quality of life (QoL). This study aimed to evaluate longitudinal QoL changes in patients with lung cancer and determine whether they differed between women and men. Methods: This longitudinal analysis included 40 patients with lung cancer who developed cisplatin-induced peripheral neuropathy during cisplatin-based chemotherapy. QoL was assessed before chemotherapy and after four cycles using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy–Lung (FACT-L). Changes over time, sex differences, and time × sex interactions were evaluated using a repeated-measures General Linear Model. p-values were adjusted for multiple comparisons using the Benjamini–Hochberg procedure. Results: Of 40 patients, 27 (67.5%) were men and 13 (32.5%) were women. On the EORTC QLQ-C30, no significant time effects were observed after adjustment for multiple comparisons. On the FACT-L, Social/Family Well-Being decreased significantly (FDR-adjusted p = 0.024), whereas Lung Cancer Subscale scores increased significantly (FDR-adjusted p = 0.044). No significant main effects of sex were identified after adjustment for multiple comparisons. No significant time × sex interactions were identified for any outcome. Conclusions: Significant changes were observed in selected QoL outcomes during cisplatin-based chemotherapy, while no significant sex-related differences in longitudinal changes were identified. Given the small and sex-imbalanced sample, the absence of significant interactions should not be interpreted as evidence of equivalent QoL changes between women and men.
SN - 2072-6694
ER -